Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.8200
-0.0185 (-2.21%)
Nov 19, 2026, 4:00 PM EST - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 72 full-time and 5 part-time employees. The number of employees did not change compared to the previous year. That makes Lineage Cell Therapeutics the 33,000th largest employer in the world and 4,275th in the United States.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$140,727
Profits / Employee
$22,766
Market Cap
209.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | 0 | - | 72 | 5 |
| Dec 31, 2024 | 77 | 2 | 2.67% | 70 | 7 |
| Dec 31, 2023 | 75 | -3 | -3.85% | 68 | 7 |
| Dec 31, 2022 | 78 | 17 | 27.87% | 70 | 8 |
| Dec 31, 2021 | 61 | 6 | 10.91% | 57 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Bicycle Therapeutics | 288 |
| Cabaletta Bio | 158 |
| Allogene Therapeutics | 152 |
| AC Immune | 122 |
| Arcturus Therapeutics Holdings | 111 |
| Immuneering | 65 |
| Bright Minds Biosciences | 26 |
LCTX News
- 7 days ago - Lineage Cell Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - Lineage Cell Therapeutics Earnings release: Q3 2026 - Filings
- 7 days ago - Lineage Cell Therapeutics Quarterly report: Q3 2026 - Filings
- 7 days ago - Lineage Cell Therapeutics reports Q3 EPS (3c), consensus (4c) - TheFly
- 7 days ago - Lineage Cell Therapeutics acquires NeuroAirmid Therapeutics - TheFly
- 7 days ago - Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 7 days ago - Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington's Disease - Business Wire
- 14 days ago - Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 - Business Wire